Compare Ganges Securitie with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate of -16.96%
Flat results in Mar 26
With ROE of 0.5, it has a Very Expensive valuation with a 0.2 Price to Book Value
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
Ganges Securitie for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleAre Ganges Securities Ltd latest results good or bad?
The latest financial results for Ganges Securities Ltd reveal significant operational challenges and volatility. In Q4 FY26, the company reported a net loss of ₹2.71 crores, marking a substantial decline from the previous quarter's performance. Revenue for the same period was ₹3.00 crores, which reflects a notable sequential drop of 73.31% from ₹11.24 crores in Q3 FY26, despite a year-on-year growth of 50.00%. This sharp revenue decline indicates severe volatility in earnings. The operating margin for Q4 FY26 was reported at -120.67%, highlighting a loss-making quarter and raising concerns about the company's cost management, particularly as employee costs of ₹4.28 crores exceeded total revenue. This unsustainable cost structure suggests that the business model may not be viable without significant adjustments. Additionally, the company’s return on equity (ROE) remains low at 0.19%, reflecting poor capita...
Read full news article Announcements 
Compliances-Reg.24(A)-Annual Secretarial Compliance
27-May-2026 | Source : BSEAnnual Secretarial Compliance Report
Announcement under Regulation 30 (LODR)-Change in Management
15-May-2026 | Source : BSEOutcome of Board Meeting
Announcement under Regulation 30 (LODR)-Newspaper Publication
15-May-2026 | Source : BSECopy of newspaper publication
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.01%)
Held by 1 FIIs (0.03%)
Sil Investments Limited (13.38%)
Navjeewan Medical Institute (6.21%)
21.69%
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
YoY Growth in quarter ended Mar 2026 is 50.00% vs -24.24% in Mar 2025
YoY Growth in quarter ended Mar 2026 is 26.95% vs 7.48% in Mar 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -4.41% vs 19.10% in Sep 2024
Growth in half year ended Sep 2025 is -52.87% vs 35.93% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -7.98% vs 11.81% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -41.05% vs 22.30% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -4.92% vs 9.08% in Mar 2025
YoY Growth in year ended Mar 2026 is -46.84% vs 45.40% in Mar 2025






